Looking for something specific?
At 9M India Limited, trust through quality, transparency, performance.
Antidiabetic Capsule Manufacturer in India
WHO-GMP certified antidiabetic hard gelatin capsule manufacturing — Biguanides, Sulphonylureas, SGLT2 inhibitors and combination formulations — for domestic institutional supply and international export across 15+ countries.
Key Highlights
-
WHO-GMP
Certified Facility -
Alu-Alu
· Alu-PVC· Strip Packing -
Export-Ready
15+ Countries -
DCGI Approved
Formulations
About
Antidiabetic capsule manufacturing at 9M India
9M India manufactures a comprehensive range of antidiabetic hard gelatin capsules at its WHO-GMP certified facility in Birkoni, Chhattisgarh. Type 2 diabetes is a global epidemic affecting over 500 million people worldwide, with the highest burden in South Asia, the Middle East and Africa — precisely the regions 9M India exports to. Our antidiabetic capsule portfolio spans all major pharmacological classes: Biguanides (Metformin), Sulphonylureas (Glibenclamide, Glimepiride, Gliclazide), SGLT2 inhibitors (Dapagliflozin), DPP-4 inhibitors (Sitagliptin, Linagliptin), and fixed-dose combination formulations — all manufactured to BP/USP standards with complete analytical testing and export documentation.
Therapeutic sub-categories — Antidiabetics
Our antidiabetics capsule range covers the following sub-categories and key molecules:
| Sub-Category | Key Molecules |
| Biguanides | Metformin HCl 500mg / 850mg / 1000mg (IR and SR) |
| Sulphonylureas | Glibenclamide 5mg, Glimepiride 1mg / 2mg / 4mg, Gliclazide 40mg / 60mg / 80mg |
| SGLT2 Inhibitors | Dapagliflozin 10mg |
| DPP-4 Inhibitors | Sitagliptin 100mg / 50mg, Linagliptin 5mg |
| Newer Agents | Dapagliflozin 10mg (SGLT2), Sitagliptin (DPP-4) |
| Combination (Metformin-based) | Metformin + Glibenclamide, Metformin + Glimepiride, Metformin + Sitagliptin, Metformin + Gliclazide SR |
| Alpha-Glucosidase Inhibitors | Acarbose 25mg / 50mg |
Enquire Now
WHY 9M INDIA FOR ANTIDIABETICS
Why pharmaceutical buyers choose 9M India for antidiabetics capsules
-
Complete antidiabetic class coverage
9M India manufactures across all major antidiabetic drug classes — from the first-line Metformin through Sulphonylureas, newer SGLT2 inhibitors and DPP-4 inhibitors. Export buyers can consolidate their entire antidiabetic procurement from a single WHO-GMP certified Indian manufacturer.
-
Metformin — the world's most prescribed antidiabetic
Metformin is the first-line treatment recommended by WHO, ADA and all major diabetes guidelines. 9M India manufactures Metformin in 500mg, 850mg and 1000mg strengths including extended-release formulations, with full institutional-scale supply capability and complete export documentation.
-
Newer agents including SGLT2 inhibitors
9M India manufactures Dapagliflozin — an SGLT2 inhibitor with proven cardiovascular and renal benefits beyond glycaemic control. This is a rapidly growing class globally and having it manufactured under WHO-GMP in India provides a significant cost advantage for export markets.
Molecule Grid
Key antidiabetics capsule formulations at 9M India
-
01
Metformin HCl 500mg | Antidiabetic | Hard gelatin capsule | Biguanide
-
02
Metformin HCl 850mg | Antidiabetic | Hard gelatin capsule | Biguanide
-
03
Glibenclamide 5mg | Antidiabetic | Hard gelatin capsule | Sulphonylurea
-
04
Glimepiride 1mg / 2mg / 4mg | Antidiabetic | Hard gelatin capsule | Sulphonylurea
-
05
Gliclazide 80mg | Antidiabetic | Hard gelatin capsule | Sulphonylurea
-
06
Dapagliflozin 10mg | Antidiabetic | Hard gelatin capsule | SGLT2 Inhibitor
-
07
Sitagliptin 100mg | Antidiabetic | Hard gelatin capsule | DPP-4 Inhibitor
-
08
Linagliptin 5mg | Antidiabetic | Hard gelatin capsule | DPP-4 Inhibitor
-
09
Metformin + Glibenclamide | Antidiabetic combination | Hard gelatin capsule | Biguanide + Sulphonylurea
-
10
Metformin + Glimepiride | Antidiabetic combination | Hard gelatin capsule | Biguanide + Sulphonylurea
Export markets & regulatory
Export markets & regulatory readiness
9M India exports antidiabetic capsules to 15+ countries across Phase 1 export markets including the UAE, Egypt, Iraq, Mexico, Russia, Kazakhstan, Sri Lanka and others in the Middle East, CIS, Africa and ASEAN. Diabetes prevalence is highest in exactly the markets we serve — making antidiabetic formulations one of our highest-demand export categories.
-
WHO-GMP Certificate
-
DCGI Manufacturing Licence
-
Certificate of Pharmaceutical Product (CoPP)
-
Certificate of Analysis (CoA) — batch-wise
-
CTD / ACTD Dossier — on request
-
Stability Data — ICH Zone IVb (30°C/75% RH)
Partner with 9M India for antidiabetics capsule supply
Whether you are sourcing first-line Metformin, Sulphonylureas, SGLT2 inhibitors or combination antidiabetic capsules — for institutional supply, government programmes or export distribution — 9M India delivers WHO-GMP certified manufacturing with complete documentation and reliable supply at scale.
-
WHO-GMP
Certified -
1,000+
Formulations -
15+ Countries
Supplied -
DCGI
Approved
Therapeutic Categories
Capsule formulations across major therapeutic categories
Our capsule portfolio covers the therapeutic areas with the highest demand across domestic distribution, institutional supply and international export markets.
We keep answer short
Frequently asked questions — antidiabetics capsules
-
01
9M India manufactures antidiabetic capsules across all major pharmacological classes including Biguanides (Metformin), Sulphonylureas (Glibenclamide, Glimepiride, Gliclazide), SGLT2 inhibitors (Dapagliflozin), DPP-4 inhibitors (Sitagliptin, Linagliptin) and fixed-dose combination formulations. All are manufactured at our WHO-GMP certified facility in Birkoni, Chhattisgarh.
-
02
Yes. 9M India manufactures Metformin Hydrochloride in both immediate-release (500mg, 850mg) and extended-release / sustained-release (500mg, 1000mg) formats. Extended-release Metformin is associated with better gastrointestinal tolerability and is increasingly preferred in clinical practice
-
03
Yes. 9M India manufactures several fixed-dose combination antidiabetic formulations including Metformin + Glibenclamide, Metformin + Glimepiride, Metformin + Sitagliptin and Metformin + Gliclazide SR. These combination capsules improve compliance in Type 2 diabetes management and are in strong demand across export markets.
-
04
Yes. 9M India is equipped to supply antidiabetic medicines for national diabetes control programmes and institutional procurement. We support large-volume orders with flexible packaging, complete GMP documentation, CoPP, batch CoA and tender compliance support.
-
05
9M India exports antidiabetic capsules to Phase 1 markets including the UAE, Egypt, Iraq, Mexico, Russia, Kazakhstan and others across the Middle East, CIS, Africa and ASEAN. Diabetes prevalence is highest in these regions, making antidiabetics a consistently high-volume export category for us.
